非硬変性門脈圧亢進症の自然経過
Background:
- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH.
Objectives:
- To learn more about how NCPH develops over time.
Eligibility:
- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse.
Design:
- Participants will have 2 screening visits.
- Visit 1: to see if they have or may develop NCPH.
- Medical history
- Physical exam
- Urine and stool studies
- Abdominal ultrasound
- Fibroscan. Sound waves measure liver stiffness.
<TAB>- Visit 2:
- Blood tests
- Abdominal MRI
- Echocardiogram
- Questionnaire
- Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This is done with a small tube inserted in a neck vein.
- They may have a liver biopsy.
- All participants will visit the clinic every 6 months for a history, physical exam, and blood tests. They will also repeat some of the screening tests yearly.
- Participants with NCPH will also have:
- Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and stomach.
- At least every 2 years: Esophagogastroduodenoscopy.
- At least every 4 years: testing including HVPG measurements and liver biopsy.
- Participants without NCPH will also have:
- Liver biopsy and HVPG measurements to see if they have NCPH.
- Every 2 years: abdominal MRI and stool studies.
- The study will last indefinitely.
調査の概要
状態
詳細な説明
Study Description:
Up to 400 subjects with noncirrhotic portal hypertension or at risk for developing noncirrhotic portal hypertension by virtue of their
underlying disease (as well as sporadic cases of noncirrhotic portal hypertension as referred to in this protocol) will be offered inclusion
in the study.
Objectives:
Primary Objective:
1. The goal of this natural history study is to generate understanding of the development and progression of NCPH. We will use our
findings to generate novel biomarkers that will enable improved follow-up of patients, assist in preventing complications, and
enhance transplant decision.
Secondary Objectives:
- Measurement of the bile acids and lipids to understand NCPH and porto-systemic shunting.
- Identification of the genetic modifiers of NCPH.
- Evaluation of hepatic transcriptome in absence and presence of NCPH.
- Characterization of microbiome signatures in NCPH.
Endpoints:
Primary Endpoints:
- Establish surveillance methods and guidelines for evaluation of NCPH.
- Develop an understanding of the biological mechanisms of the progression of NCPH.
- Identification of novel biomarkers correlating with NCPH progression.
Secondary Endpoints:
- Measurement of bile acids fractionated and total, as well as lipid panel to establish cut-off levels correlating with NCPH severity.
- Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype.
- Identification of novel markers of fibrosis or the development of hepatic neoplasia from transcriptome analysis.
- Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Theo Heller, M.D.
- 電話番号:(301) 402-7147
- メール:theoh@intra.niddk.nih.gov
研究連絡先のバックアップ
- 名前:Jaha F Norman-Wheeler
- 電話番号:(301) 435-6122
- メール:jaha.norman-wheeler@nih.gov
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- 募集
- National Institutes of Health Clinical Center
-
コンタクト:
- Jaha Norman-Wheeler
- 電話番号:301-435-6122
- メール:jaha.norman-wheeler@nih.gov
-
コンタクト:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- 電話番号:TTY dial 711 (800) 411-1222
- メール:ccopr@nih.gov
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Subjects with diagnosis of noncirrhotic portal hypertension above age of 12 years
説明
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male or female, aged >= 18 years of age, and minors 12-17 years of age.
- Women of childbearing potential must agree to use birth control unless they are menopausal or had hysterectomy.
- Known diagnosis of NCPH, or to be at the risk for NCPH by virtue of underlying disease processes such as but not limited to; CGD, SCD, Mastocytosis, CVID, CF, and CHF.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy.
- Evidence of other forms of liver disease that typically result in cirrhosis.
- Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (>10,000 IU/mL).
- Hepatitis C as defined by the presence of hepatitis C RNA in serum.
- Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.
- Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of >45% and serum ferritin levels of >300 ng/ml for men and >250 ng/ml for women will undergo genetic testing for hemochromatosis.
- Bile duct obstruction as suggested by imaging studies done within the previous six months.
- The presence of cirrhosis confirmed by liver biopsy.
- Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during subject interviews by subject self-report).
- Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal <6.6ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.
- Evidence of cholangiocarcinoma as suggested by liver histology.
- Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.
- Inability to comply or give written informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Adult with absence of Portal Hypertension
Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination. |
|
Adult with presence of Portal Hypertension
Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg). |
|
Minors likely to have the absence of Portal Hypertension
Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination. |
|
Minors likely to have the presence of Portal Hypertension
Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5). |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To study the natural history of non cirrhotic portal hypertension. It is an ongoing study.
時間枠:Ongoing
|
natural history study |
Ongoing
|
協力者と研究者
捜査官
- 主任研究者:Theo Heller, M.D.、National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
出版物と役立つリンク
一般刊行物
- Sarin SK, Aggarwal SR. Idiopathic portal hypertension. Digestion. 1998 Jul-Aug;59(4):420-3. doi: 10.1159/000007502. No abstract available.
- Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, Lesmana LA, Guha Mazumder D, Omata M, Qureshi H, Raza RM, Sahni P, Sakhuja P, Salih M, Santra A, Sharma BC, Sharma P, Shiha G, Sollano J; Members of the APASL Working Party on Portal Hypertension. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007 Sep;1(3):398-413. doi: 10.1007/s12072-007-9010-9. Epub 2007 Sep 11.
- Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011 Sep 2;54(3):1071-81. doi: 10.1002/hep.24422. Epub 2011 Jul 21.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 内分泌系疾患
- 血管疾患
- 心血管疾患
- 男性の泌尿生殖器疾患
- 病理学的状態、解剖学的
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 心臓疾患
- 遺伝性疾患、先天性疾患
- 免疫系疾患
- 気道疾患
- 消化器系疾患
- 肺疾患
- 幼児、新生児、病気
- 膵臓の病気
- 性腺疾患
- 先天異常
- 心血管異常
- 先天性心疾患
- 性発達障害
- 泌尿生殖器の異常
- 性染色体異常
- 染色体異常
- 性の発達の性染色体障害
- 肥大
- 性腺形成不全
- 先天性、遺伝性、および新生児の疾患と異常
- 病理学的状態、徴候および症状
- 特発性非肝硬変性門脈圧亢進症
- 肝疾患
- 免疫不全症候群
- 高血圧、ポータル
- 嚢胞性線維症
- 静脈瘤
- ターナー症候群
- 脾腫
- 肝線維症、先天性
その他の研究ID番号
- 150108
- 15-DK-0108
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
This is a longitudinal study and it is not yet known if and when IPD will be made available.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。